Biocept's patented collection tubes now available from VWR for the safe transport of patient specimens containing both circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) at room temperature SAN DIEGO , June 11, 2018 /PRNewswire/ -- Biocept, Inc .
SAN DIEGO , May 29, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that President and CEO Michael
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , May 15, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
SAN DIEGO , May 8, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
Letter to the editor highlights capability of Target Selector™ test to detect ROS1, a lung cancer biomarker used to qualify patients for targeted therapies that can improve treatment outcomes SAN DIEGO , May 1, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
Peer-reviewed article in Oncology & Hematology Review highlights capability of Target Selector™ to detect a key biomarker to qualify lung cancer patients for targeted therapy when tissue biopsy is inadequate SAN DIEGO , April 27, 2018 /PRNewswire/ -- Biocept, Inc.
Company to also co-host roundtable discussion SAN DIEGO , April 6, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with
Company to also co-host roundtable discussion SAN DIEGO , April 3, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with
Expands intellectual property position to 26 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers found in tissue, blood and other biological sources SAN DIEGO , March 29, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
2017 revenues increased 57% due to higher reimbursement for Target Selector™ liquid biopsy tests and the impact of conversion to accrual-based revenue recognition Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , March 28, 2018 /PRNewswire/ -- Biocept, Inc.
